Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis.

Huijuan LiHedong HanChuling LiRanpu WuZhaofeng WangYimin WangPing ZhanTangfeng LvFang ZhangYong SongHongbing Liu

Published in: Therapeutic advances in medical oncology (2023)

Serplulimab plus chemotherapy seems to be superior first-line immunotherapy combination for patients with ES-SCLC. PD-1 + chemo seems to outperform PD-L1 + chemo in PFS.

Keyphrases

small cell lung cancer
locally advanced
systematic review
photodynamic therapy
cancer therapy
rectal cancer
combination therapy
meta analyses
squamous cell carcinoma
drug delivery
case control